# Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Source: https://onco.cc/trials/nct05898399/  
OnCo record `nct05898399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Olaparib in advanced solid tumours, run by Artios Pharma Ltd, now recruiting.

## Summary

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) is a phase 1/2 interventional study registered as NCT05898399 by Artios Pharma Ltd, with 181 participants planned, started 2023-06-30 and due to reach its primary completion in 2028-06-30. Interventions recorded: ART6043 and Olaparib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05898399
- Phase: 1/2
- Setting: A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
- Sponsor: Artios Pharma Ltd
- Enrolled: 181

## Sources

- ClinicalTrials.gov NCT05898399: https://clinicaltrials.gov/study/NCT05898399

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct05898399.json